Teresa Short
Family · Excelsior Springs, MONPI 1235117110
Payments from drug & device makers
Across 455 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$747
- Novo Nordisk$594
- Lilly USA, LLC$571
- Otsuka America Pharmaceutical, Inc.$557
- Amgen$494
- plus $4K from 34 others
What the payments were for
- Food & beverage$8,434100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 113 | $1,903 |
| AstraZeneca | 38 | $747 |
| Novo Nordisk | 29 | $594 |
| Lilly USA, LLC | 34 | $571 |
| Otsuka America Pharmaceutical, Inc. | 25 | $557 |
| Amgen | 31 | $494 |
| Vanda Pharmaceuticals Inc. | 8 | $438 |
| Pfizer | 32 | $437 |
| GSK | 20 | $436 |
| Teva Pharmaceuticals USA, Inc. | 25 | $414 |
| Boehringer Ingelheim | 12 | $173 |
| Mylan Specialty L.p. | 11 | $173 |
| Merck | 8 | $159 |
| Sumitomo Pharma America, Inc. | 3 | $147 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $144 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $117 |
| Lundbeck LLC | 5 | $101 |
| Organon | 5 | $100 |
| Astellas Pharma US Inc | 4 | $95 |
| Bayer | 5 | $82 |
| Johnson & Johnson | 5 | $72 |
| Phathom Pharmaceuticals, Inc. | 3 | $55 |
| Dexcom, Inc. | 2 | $50 |
| Biohaven Pharmaceuticals, Inc. | 2 | $45 |
| Nevro Corp. | 2 | $42 |
| Novartis | 3 | $41 |
| Abbott | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Alkermes, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Vertex | 1 | $18 |
| Biofire Diagnostics, LLC | 1 | $17 |
| Biomerieux Inc | 1 | $17 |
| Viatris Specialty LLC | 1 | $17 |
| Verona Pharma, Inc. | 1 | $16 |
| Endo Pharmaceuticals Inc. | 1 | $15 |
| Neurelis, Inc. | 1 | $15 |
| Electromed, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Supernus Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,434 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 124 | $139,867 |
| JardianceEmpagliflozin | 24 | $40,123 |
| EliquisApixaban | 35 | $36,253 |
| XareltoRivaroxaban | 29 | $31,958 |
| MounjaroTirzepatide | 26 | $29,023 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $22,070 |
| TrulicityDulaglutide | 16 | $21,507 |
| JanuviaSitagliptin Phosphate | 17 | $15,336 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $11,532 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $11,250 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $8,057 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $7,847 |
| Novolog FlexpenInsulin Aspart | 24 | $6,182 |
| LinzessLinaclotide | 11 | $5,847 |
| Duloxetine Hcl | 194 | $5,136 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $594 | $139,867124 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $173 | $51,65540 claims |
| Lilly USA, LLCMounjaro, Trulicity | $571 | $50,53042 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arexvy | $436 | $37,43163 claims |
| PfizerEliquis | $437 | $36,25335 claims |
| Johnson & JohnsonXarelto | $72 | $31,95829 claims |
| MerckJanuvia | $159 | $15,33617 claims |
| AbbVieLinzess | $1,903 | $5,84711 claims |
| AstraZenecaSymbicort | $747 | $3,48915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,812 family providers in Missouri.
Other family in Excelsior Springs
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Laura HedigerSpringfield$71K
- Rebecca SeabaughSaint Louis$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.